Cellectis SA
CLLS3.015USD
+0.065+2.20%
取引時間 （ET）15分遅れの株価
217.36M時価総額
損失額直近12ヶ月PER
詳細情報 Cellectis SA 企業名
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
企業情報
企業コードCLLS
会社名Cellectis SA
上場日Feb 06, 2007
最高経営責任者「CEO」Dr. David Sourdive, Ph.D.
従業員数224
証券種類Depository Receipt
決算期末Feb 06
本社所在地8, rue de la Croix Jarry
都市PARIS
証券取引所NASDAQ Global Market Consolidated
国France
郵便番号75013
電話番号33181691600
ウェブサイトhttps://www.cellectis.com/
企業コードCLLS
上場日Feb 06, 2007
最高経営責任者「CEO」Dr. David Sourdive, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Non-Executive Director
Non-Executive Director
--
--
Dr. Cecile Chartier, Ph.D.
Dr. Cecile Chartier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
データなし
地域別USD
会社名
収益
比率
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
事業別
地域別
データなし
株主
更新時刻: Mon, May 26
更新時刻: Mon, May 26
株主統計
種類
株主統計
株主統計
比率
Long Focus Capital Management LLC
6.53%
B Group, Inc.
4.50%
UBS Asset Management (Switzerland)
3.98%
Pfizer Inc
3.86%
UBS Asset Management (Americas) LLC
2.55%
Other
78.58%
株主統計
株主統計
比率
Long Focus Capital Management LLC
6.53%
B Group, Inc.
4.50%
UBS Asset Management (Switzerland)
3.98%
Pfizer Inc
3.86%
UBS Asset Management (Americas) LLC
2.55%
Other
78.58%
種類
株主統計
比率
Investment Advisor
14.08%
Hedge Fund
6.68%
Corporation
3.86%
Investment Advisor/Hedge Fund
0.49%
Research Firm
0.18%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
74.66%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
78
18.32M
25.34%
-2.37M
2025Q1
83
18.44M
25.50%
-2.58M
2024Q4
88
17.72M
24.57%
+1.29M
2024Q3
106
16.31M
22.62%
-2.61M
2024Q2
105
14.76M
20.47%
-2.65M
2024Q1
113
14.77M
20.56%
-2.69M
2023Q4
124
14.69M
20.46%
-8.13M
2023Q3
142
13.62M
24.51%
-10.91M
2023Q2
155
16.13M
29.02%
-9.56M
2023Q1
162
17.33M
31.20%
-2.13M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Long Focus Capital Management LLC
4.72M
6.53%
+100.00K
+2.17%
Mar 31, 2025
B Group, Inc.
3.26M
4.5%
+175.00K
+5.68%
Mar 31, 2025
UBS Asset Management (Switzerland)
2.88M
3.98%
+1.44M
+100.00%
Mar 31, 2025
Pfizer Inc
2.79M
3.86%
+2.79M
--
Dec 31, 2023
UBS Asset Management (Americas) LLC
1.85M
2.55%
+1.85M
--
Mar 31, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
Macquarie Investment Management
226.88K
0.31%
--
--
Mar 31, 2025
Bellecapital AG
226.07K
0.31%
--
--
Nov 30, 2024
Baillie Gifford & Co.
139.05K
0.19%
-151.38K
-52.12%
Mar 31, 2025
Millennium Management LLC
103.85K
0.14%
-430.70K
-80.57%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
比率0%
Avantis International Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
